A Phase 1 interventional study of Alprazolam 0.5 mg and Alprazolam 0.5 mg in Anxiety Disorders, sponsored by GlaxoSmithKline. Completed. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-14.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing alprazolam in Anxiety Disorders — 1 open to participants now, 1 under way, none of them phase 3. Alprazolam · Anxiety Disorders.
Among the 13 studies testing alprazolam in Anxiety Disorders, this one is the 9th largest by enrollment, is one of 3 that started in 2010, is one of 3 in phase 1, and was the 7th registered.
7,220 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.
Browse Anxiety Disorders studies →1 of the 13 studies testing alprazolam in Anxiety Disorders is open now, in 1 country. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Alprazolam: first FDA approval 1981 (XANAX). What it is approved for, and how studies give it, is on its page →
Of the 945 Anxiety Disorders studies recruiting now, 417 (44%) set no upper age limit and 461 (49%) stop at 75 or younger; 233 take children under 18; 318 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 2 · Phase 4 4
First in 1997; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 80 across 6,071 interventional studies indexed under Anxiety Disorders.
Median enrollment 48 across the 13 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
24 studies in Anxiety Disorders by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 24 finished, 3 (13%) have results posted.
Among the 24 studies in Anxiety Disorders by GlaxoSmithKline, this one is the 12th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2010, is one of 17 in phase 1, and was the 19th registered.
GlaxoSmithKline’s Anxiety Disorders studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing alprazolam in Anxiety Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 24 in Anxiety Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study was to confirm if two formulations of alprazolam (tablets) are bioequivalent.
Test product was Zamoprax® 0.5 mg (GlaxoSmithKline) and reference product Tafil® 0.5 mg (Pharmacia \& Upjohn). One tablet was the single dosage.
The study was prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods, under fasting conditions.
The population was composed of 28 healthy volunteers, both genders, adults between 18-50 years.
The comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Free will participation according to Mexican regulation, Helsinki Declaration, and Good Clinical Practice.
Healthy, between 18 and 50 years. between 18 and 27.5 In good health by complete medical history and laboratory tests. Blood pressure 130-90/ 90-60 mm Hg; heart rate 55-100 beat per minute, respiratory rate 14-20 movements per minute.
Laboratory tests +/- 10% of normal interval (blood cytology, blood chemistry 27 elements, and C antigens, , urinalysis, anti-doping, pregnancy, ) -
Exclusion Criteria:
Alteration of vital signs Not complying with inclusion criteria History of cardiovascular, kidney, hepatic, muscular, metabolic, gastrointestinal (including constipation), neurologic, endocrine, hematopoietic (any kind of anemia), asthma, mental or organic disease. Those suffering from muscular trauma 21 days before the beginning of the study.
Requirement of any kind of medication during the course of the study, except study medication.
History of dyspepsia, gastritis, esophagitis, duodenal or gastric ulcer. Exposure to medications known as inducers or inhibitors of hepatic enzymes or administration of potentially toxic medication in the 30 days before the study beginning.
Administration of any medication in the 14 days or 5 half-lives (whatever longer) previous to the beginning of the study.
Hospitalization for any cause in the seven months before the beginning of the study.
Administration of drugs in the 60 days before the study. Allergy to any antibiotic or non-steroidal anti-inflammatory analgesic. Alcohol ingestion or intake of beverages containing xanthines (coffee, tea, cocoa, chocolate, mate, cola drinks) or ingestion of charcoal grilled food or grapefruit or orange juice in the 72 hours before the hospitalization or tobacco smoking in the 72 hours before the beginning of the study.
Blood donation or loss => 450 ml in the 60 days before the beginning of the study.
History of drug or alcohol abuse. Positive pregnancy test or antidoping test Special diet requirement, for instance vegetarian diet. Inability to understand nature, aims, and possible consequences of the study. Evidence of non-cooperative attitude during the study. Breast-feeding. Females on hormonal treatment.
-
-
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
initial administration of reference and cross-over to test
Drug: Alprazolam 0.5 mg
initial administration of test and cross-over to reference
Drug: Alprazolam 0.5 mg
Reference product
Also known as: Tafil 0.5 mg Pfizer Pharmaceuticals LLC
Test product
Also known as: Zamoprax 0.5 mg GLAXOSMITHKLINE MEXICO SA de CV
Peak Plasma Concentration (CMAX) of alprazolam
Pharmacokinetics
Time frame: 0.0, 0.167, 0.333, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 9.0, 12.0, 18.0, 22.0, 36.0, 48.0, 60.0, and 72.0 hours postdosage
Area under the plasma concentration versus time curve (AUC) of Alprazolam
Pharmacokinetics
Time frame: 0.0, 0.167, 0.333, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 9.0, 12.0, 18.0, 22.0, 36.0, 48.0, 60.0, and 72.0 hours postdosage
No study locations are listed for this record.
Ran from Dec 2010 to primary completion in Dec 2010, 0 months.
Of 71 phase 1 interventional studies under Anxiety Disorders, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 0 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alprazolam